SPY415.98+3.81 0.92%
DIA341.24+3.12 0.92%
IXIC13,950.22+163.95 1.19%

BRIEF-Esperion Says Nexletol Tablet, Ezetimibe And Atorvastatin Combination Lowered Bad Cholesterol By 60.5% Vs Placebo In Phase 2 Study

· 03/17/2021 16:14
BRIEF-Esperion Says Nexletol Tablet, Ezetimibe And Atorvastatin Combination Lowered Bad Cholesterol By 60.5% Vs Placebo In Phase 2 Study

- Esperion Therapeutics Inc ESPR.O:

  • NEXLETOL® (BEMPEDOIC ACID) TABLET, EZETIMIBE AND ATORVASTATIN COMBINATION LOWERED BAD CHOLESTEROL BY 60.5% VERSUS. PLACEBO IN PHASE 2 STUDY

  • ESPERION THERAPEUTICS INC - ADVERSE EVENTS IN PHASE 2 STUDY WERE PREDOMINANTLY MILD OR MODERATE IN SEVERITY

Source text for Eikon: ID:nGNX16ls55

Further company coverage: ESPR.O


((Reuters.Briefs@thomsonreuters.com;))